These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1801 related articles for article (PubMed ID: 27338353)
1. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Sarkar S; Raymick J; Imam S Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353 [TBL] [Abstract][Full Text] [Related]
2. The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling. Baluchnejadmojarad T; Eftekhari SM; Jamali-Raeufy N; Haghani S; Zeinali H; Roghani M Exp Gerontol; 2017 Dec; 100():70-76. PubMed ID: 29107062 [TBL] [Abstract][Full Text] [Related]
3. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms. Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review. Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973 [TBL] [Abstract][Full Text] [Related]
5. Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress. Nataraj J; Manivasagam T; Thenmozhi AJ; Essa MM Nutr Neurosci; 2016 Jul; 19(6):237-46. PubMed ID: 25730317 [TBL] [Abstract][Full Text] [Related]
6. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models. Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438 [TBL] [Abstract][Full Text] [Related]
7. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress. Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429 [TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge. Miraglia F; Betti L; Palego L; Giannaccini G Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035 [TBL] [Abstract][Full Text] [Related]
9. ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats. Singh S; Mishra A; Shukla S Mol Neurobiol; 2016 Sep; 53(7):4286-301. PubMed ID: 26223802 [TBL] [Abstract][Full Text] [Related]
10. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model. Rai SN; Yadav SK; Singh D; Singh SP J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287 [TBL] [Abstract][Full Text] [Related]
11. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease. Kim M; Cho KH; Shin MS; Lee JM; Cho HS; Kim CJ; Shin DH; Yang HJ Int J Mol Med; 2014 Apr; 33(4):870-8. PubMed ID: 24535622 [TBL] [Abstract][Full Text] [Related]
12. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies. Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513 [TBL] [Abstract][Full Text] [Related]
14. Current disease modifying approaches to treat Parkinson's disease. Lindholm D; Mäkelä J; Di Liberto V; Mudò G; Belluardo N; Eriksson O; Saarma M Cell Mol Life Sci; 2016 Apr; 73(7):1365-79. PubMed ID: 26616211 [TBL] [Abstract][Full Text] [Related]
15. Protective role of apigenin on rotenone induced rat model of Parkinson's disease: Suppression of neuroinflammation and oxidative stress mediated apoptosis. Anusha C; Sumathi T; Joseph LD Chem Biol Interact; 2017 May; 269():67-79. PubMed ID: 28389404 [TBL] [Abstract][Full Text] [Related]
16. Neuroprotective strategies to prevent and treat Parkinson's disease based on its pathophysiological mechanism. Lee Y; Kim MS; Lee J Arch Pharm Res; 2017 Oct; 40(10):1117-1128. PubMed ID: 28952032 [TBL] [Abstract][Full Text] [Related]
17. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models. Xiong N; Long X; Xiong J; Jia M; Chen C; Huang J; Ghoorah D; Kong X; Lin Z; Wang T Crit Rev Toxicol; 2012 Aug; 42(7):613-32. PubMed ID: 22574684 [TBL] [Abstract][Full Text] [Related]
19. Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease. Masilamoni GJ; Smith Y J Neural Transm (Vienna); 2018 Mar; 125(3):337-363. PubMed ID: 28861737 [TBL] [Abstract][Full Text] [Related]
20. Marine-Derived Natural Compounds for the Treatment of Parkinson's Disease. Huang C; Zhang Z; Cui W Mar Drugs; 2019 Apr; 17(4):. PubMed ID: 30978965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]